Protective Effects of Nobiletin Against Endotoxic Shock in Mice Through Inhibiting TNF-α, IL-6, and HMGB1 and Regulating NF-κB Pathway.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 7600105 Publication Model: Print Cited Medium: Internet ISSN: 1573-2576 (Electronic) Linking ISSN: 03603997 NLM ISO Abbreviation: Inflammation Subsets: MEDLINE
    • Publication Information:
      Publication: 1999- : New York, NY : Kluwer Academic/Plenum Publishers
      Original Publication: New York, Plenum Press.
    • Subject Terms:
      Flavones/*therapeutic use ; HMGB1 Protein/*antagonists & inhibitors ; Interleukin-6/*antagonists & inhibitors ; NF-kappa B/*metabolism ; Shock, Septic/*prevention & control ; Tumor Necrosis Factor-alpha/*antagonists & inhibitors; Animals ; Flavones/adverse effects ; HMGB1 Protein/blood ; Interleukin-6/blood ; Kidney/pathology ; Lipopolysaccharides/toxicity ; Liver/pathology ; Lung/pathology ; Macrophages/immunology ; Male ; Mice ; Shock, Septic/drug therapy ; Tumor Necrosis Factor-alpha/blood
    • Abstract:
      Nobiletin (NOB), the major bioactive component of polymethoxyflavones in citrus fruits, has been reported possessing significant biological properties. The purpose of the present study was to investigate the protective role of NOB on lipopolysaccharide (LPS)-induced endotoxic shock in mice. We found pretreatment with NOB increases the survival rate of mice after endotoxin injection. The present study clearly demonstrates that pretreatment with NOB decreases the production of early pro-inflammatory cytokines TNF-α, IL-6, and late-phase mediator HMGB1 in serum and tissues of kidney, lung, and liver. The histopathological study indicates that NOB administration significantly attenuate tissues injury induced by LPS. Moreover, NOB suppresses the activity of nuclear factor-kappa B (NF-κB). These results suggest that NOB protects mice against LPS-induced endotoxic shock through inhibiting the production of TNF-α, IL-6, and HMGB1 and the activation of NF-κB, which elucidate that NOB may be a promising drug candidate for the treatment of septic shock.
    • References:
      J Mol Med (Berl). 2006 Jan;84(1):65-74. (PMID: 16284791)
      Acta Anaesthesiol Taiwan. 2013 Mar;51(1):28-33. (PMID: 23711603)
      PLoS One. 2012;7(10):e47403. (PMID: 23071799)
      Int J Immunopharmacol. 2000 Jan;22(1):83-90. (PMID: 10684991)
      Curr Med Chem. 2005;12(3):357-74. (PMID: 15723624)
      Lancet Infect Dis. 2009 May;9(5):281-90. (PMID: 19393958)
      Exp Mol Pathol. 2008 Dec;85(3):214-22. (PMID: 18952078)
      Res Vet Sci. 2013 Jun;94(3):590-5. (PMID: 23151462)
      J R Coll Surg Edinb. 2000 Jun;45(3):178-82. (PMID: 10881485)
      Life Sci. 2006 May 1;78(23):2689-96. (PMID: 16337971)
      Int Immunopharmacol. 2012 Dec;14(4):369-74. (PMID: 22878138)
      Immunobiology. 2015 Mar;220(3):406-13. (PMID: 25454811)
      J Transl Med. 2011 May 13;9:61. (PMID: 21569464)
      Chem Biol Interact. 2012 Apr 15;197(1):31-9. (PMID: 22465177)
      Arch Biochem Biophys. 2013 Sep 1;537(1):72-81. (PMID: 23831508)
      J Infect Dis. 1990 Aug;162(2):421-7. (PMID: 2373872)
      J Surg Res. 2009 Mar;152(1):46-53. (PMID: 19027920)
      Nature. 1990 Dec 6;348(6301):550-2. (PMID: 2147233)
      Biol Reprod. 2002 Aug;67(2):668-73. (PMID: 12135912)
      Crit Care Med. 2001 Jul;29(7):1303-10. (PMID: 11445675)
      Science. 1992 Oct 23;258(5082):593-7. (PMID: 1411569)
      Gene. 2008 Nov 1;423(2):97-107. (PMID: 18718859)
      Biol Pharm Bull. 2007 Apr;30(4):772-8. (PMID: 17409518)
      J Nutr. 2005 Dec;135(12 Suppl):2987S-2992S. (PMID: 16317159)
      Food Chem Toxicol. 2013 Dec;62:847-55. (PMID: 24161485)
      J Infect Dis. 1998 Feb;177(2):388-94. (PMID: 9466526)
      Nat Rev Drug Discov. 2003 May;2(5):391-405. (PMID: 12750742)
      Biosci Biotechnol Biochem. 2006 Jan;70(1):178-92. (PMID: 16428836)
      Chang Gung Med J. 2005 Oct;28(10):673-82. (PMID: 16382751)
      J Ethnopharmacol. 2008 Aug 13;118(3):495-502. (PMID: 18599229)
      Science. 1999 Jul 9;285(5425):248-51. (PMID: 10398600)
      FEBS Lett. 2007 Jul 31;581(19):3723-33. (PMID: 17428476)
      Chest. 1997 Jul;112(1):235-43. (PMID: 9228382)
      Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S490-7. (PMID: 16237652)
      Clin Chem. 1999 Jan;45(1):7-17. (PMID: 9895331)
      Am J Physiol Lung Cell Mol Physiol. 2006 Apr;290(4):L622-L645. (PMID: 16531564)
      Nat Rev Immunol. 2008 Nov;8(11):837-48. (PMID: 18927578)
      Mol Med Today. 1999 Mar;5(3):123-32. (PMID: 10203736)
      J Pharm Biomed Anal. 2014 Feb;89:251-6. (PMID: 24316425)
      J Biomed Res. 2010 Sep;24(5):389-94. (PMID: 23554654)
      Cell. 2008 Feb 8;132(3):344-62. (PMID: 18267068)
    • Contributed Indexing:
      Keywords: NF-κB; endotoxic shock; nobiletin; pro-inflammatory cytokine
    • Accession Number:
      0 (Flavones)
      0 (HMGB1 Protein)
      0 (HMGB1 protein, mouse)
      0 (Interleukin-6)
      0 (Lipopolysaccharides)
      0 (NF-kappa B)
      0 (Tumor Necrosis Factor-alpha)
      D65ILJ7WLY (nobiletin)
    • Publication Date:
      Date Created: 20160206 Date Completed: 20170110 Latest Revision: 20181113
    • Publication Date:
      20221213
    • Accession Number:
      10.1007/s10753-016-0307-5
    • Accession Number:
      26846885